Company Intelligence
Medtronic is the world's largest medical device company, developing and manufacturing therapeutic medical devices for chronic diseases. The company operates through four segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes. Medtronic's products include cardiac pacemakers, spinal implants, surgical robots, insulin pumps, and neurostimulators. Incorporated in Ireland for tax purposes, the company's operational headquarters and largest employee base are in Minneapolis, Minnesota.
Medical Devices
Headquarters
Dublin, Ireland (operational HQ: Minneapolis, MN)
Employees
~95,000
Revenue
$32.4B (FY2025)
Fiscal Year End
April 30
Founded
1949
Current leadership team based on public filings and announcements.
Geoff Martha
CEO
Karen Parkhill
CFO
Key events and changes that sales teams should know about.
Advanced the Hugo robotic-assisted surgery platform through expanded clinical evaluations and regulatory submissions, positioning Medtronic to compete with Intuitive Surgical in the fast-growing surgical robotics market.
2025-01
Expanded AI-powered surgical planning and navigation tools across orthopedic, spine, and cranial procedures, leveraging machine learning to help surgeons plan, visualize, and execute complex procedures with greater precision.
2024-11
Continued investing in diabetes technology including next-generation insulin pump systems and continuous glucose monitoring integrations, while navigating the impact of GLP-1 weight-loss drugs on the broader diabetes device market.
2024-09
Q2 FY2025 revenue grew 5% organically to $8.4B, with Cardiovascular up 6% and Neuroscience up 8%, showing accelerating growth momentum as new product launches gain traction across multiple business segments.
2024-11
Addressed investor concerns about the impact of GLP-1 receptor agonist drugs (like Ozempic) on medical device demand, arguing that weight-loss drugs will expand the treatable patient pool for many MedTech categories while acknowledging some headwinds in bariatric surgery.
2024-06
Medtronic's Hugo robotic surgery platform is one of the most watched product launches in MedTech. If Hugo gains broad regulatory clearance and hospital adoption, it could disrupt Intuitive Surgical's near-monopoly in soft-tissue robotic surgery -- a market that's expected to grow significantly as robotic-assisted procedures expand beyond urology and gynecology into general surgery and thoracic procedures. Vendors in the surgical technology, hospital IT, and perioperative workflow spaces should understand this competitive dynamic.
The GLP-1 drug impact on medical devices is a major theme for Medtronic and the broader MedTech industry. Drugs like Ozempic and Mounjaro are reducing the number of bariatric surgeries and potentially the prevalence of obesity-related conditions that drive demand for cardiac and diabetes devices. Medtronic's response -- emphasizing that healthier, longer-living patients still need devices and that GLP-1s will expand the treatable population -- is a critical narrative for anyone analyzing MedTech market dynamics.
Medtronic's April 30 fiscal year end creates a unique procurement rhythm. Q4 runs February through April, which means budget finalization and large purchase decisions often happen in March and April. This is unusual in MedTech, where many peers follow the calendar year. Sales teams targeting Medtronic should plan their engagement calendar around this April close, and those selling into hospitals should understand that Medtronic's own fiscal-year-end discounting and deal activity peaks in the February-April window.
Key competitors based on market analysis and public filings.
Medtronic's fiscal year ends on April 30. This means FY2025 runs from May 1, 2024 through April 30, 2025. Their Q4 budget and procurement period falls in February through April, an unusual window that creates distinct selling opportunities for vendors targeting Medtronic.
Medtronic generates approximately $32.4 billion in annual revenue as of FY2025, making it the world's largest pure-play medical device company. The Cardiovascular segment is the largest, followed by Neuroscience, Medical Surgical, and Diabetes.
Medtronic is legally incorporated in Dublin, Ireland (following a 2015 inversion via the Covidien acquisition), but its operational headquarters, CEO office, and largest employee population are in Minneapolis, Minnesota, where the company was founded by Earl Bakken in 1949.
The impact of GLP-1 weight-loss drugs (Ozempic, Mounjaro, etc.) on Medtronic is nuanced. Bariatric surgery volumes have declined, which affects Medtronic's surgical business. However, Medtronic argues that patients living longer and healthier lives due to GLP-1s will still need cardiac devices, spinal implants, and neurostimulators -- potentially expanding the overall addressable market over time. The diabetes device segment faces the most direct uncertainty as GLP-1s reduce insulin dependence for some Type 2 patients.
Medtronic employs approximately 95,000 people globally, with the largest concentration in the Minneapolis-St. Paul metropolitan area. The workforce spans engineering, manufacturing, clinical research, and commercial operations across more than 150 countries.
See leadership changes, strategic initiatives, earnings insights, and buying signals for Medtronic — updated continuously.
